Somatogen (SMTG) | Stock Discussion Forums

SiliconInvestor

sponsor

Sponsor

Biotech / Medical | Somatogen (SMTG)

Previous 10 | Next 10

To: Bharat H. Barai who wrote (68)	2/28/1997 10:30:00 PM
From: TCcutter	of 442

Your post was excellent. I just found this thread. I've been long on SMTG for several years. I'm a practicing general surgeon and believe in the need for "Oxygen Therapeutics" whether to prime the pump for CV surgery or as back up for run of the mill operations or emergencies. Patients are demanding alternatives and we spend big bucks doing autologous banking for blood which is never used. Optro fits these and other needs well and the benefits of recombinant production can't be disputed. I've read an excellent institutional report of "Oxygen Therapeutics" by Stover & Ass. 9/1996. If anyone is interested I could provide more info, if it's old news sorry to take up time. Just drop me an email.

Share	Recommend \| Keep \| Reply \| Mark as Last Read

To: TCcutter who wrote (70)	3/1/1997 7:03:00 AM
From: AgAuUSA	of 442

To All, Does anyone know the dates for the following conference? Thanx. Somatogen, Inc. to Present at Colorado Bio Investment Conference Source: PR Newswire COLORADO BIO INVESTMENT CONFERENCE, DENVER, Feb. 27 /PRNewswire/ via Individual Inc. -- Somatogen, Inc. is a presenter at the 1997 COLORADO BIO INVESTMENT CONFERENCE. Somatogen, Inc. (Nasdaq: SMTG) presented audiences at the Colorado Bio Investment Conference with a corporate overview and an update of the market opportunities for Optro(R), the company's recombinant human hemoglobin. Optro is a therapeutic designed to deliver oxygen and restore volume in the treatment of acute blood loss associated with surgery. Somatogen is developing Optro in collaboration with Eli Lilly & Company. Optro may provide significant safety benefits over donated human blood in that it is universally compatible with all blood types and eliminates the possibility of blood-borne infections. At commercialization, Optro will be provided in a form that is ready for rapid infusion in a manner similar to blood and is suitable for pharmacy storage under refrigerated conditions. Somatogen is currently conducting a late Phase II, multi-center, intraoperative blood loss study in North America, and plans to initiate a cardiopulmonary bypass study in the near future. Additionally, the Company is conducting Phase I studies to study the ability of recombinant hemoglobin to stimulate hematopoiesis in patients with End Stage Renal Disease and primary bone marrow cancer. For further information, contact Nanita Waddell, Somatogen, Inc., Investor Relations Administrator at 2545 Central Avenue, Boulder, CO 80301, or 303-541-3311. For information via facsimile at no cost, dial 800-669-9307, or see our Web page at members.aol.com Optro(R) is a registered trademark of Somatogen. SOURCE Somatogen, Inc. /CONTACT: Nanita Waddell, Investor Relations for Somatogen, 303-541-3311/ (SMTG) CO: Somatogen, Inc. ST: Colorado IN: MTC SU: KS-EQ -- LATH004 -- 2884 02/27/97 09:29 EST prnewswire.com [02-27-97 at 12:00 EST, PR Newswire]

Share	Recommend \| Keep \| Reply \| Mark as Last Read

To: TCcutter who wrote (70)	3/3/1997 5:34:00 PM
From: Todd King	of 442

TCcutter. Welcome to the thread. It is good to have professionals in the area onboard. I read the Stover report, and found it to be exceptional. However, it was a bit noncommittal on the subject of economics. As my background is in chemical engineering, I have a feeling for the economics on the production side. However, I am uncertain of the premium to donated blood that Optro might command in the marketplace. One would think that such a premium should exist, and could be significant, as the potential downside of choosing donated blood over Optro could be substantial should the patient subsequently develop serious transfusion-related complications. That is, the complications would be the direct result of a economic decision of the provider. This, of course, is simplistic in that it assumes that the two choices would be equivalent from a safety/efficacy point of view. Would appreciate any thoughts that people might have in regard to this question. Cheers, Todd

Share	Recommend \| Keep \| Reply \| Mark as Last Read

To: Todd King who wrote (73)	3/3/1997 10:38:00 PM
From: TCcutter	of 442

Todd, I agree that there should be a premium. My patients are concerned about infection from transfusions but there are significant risks with compatability too, even when autologous blood( their own) is donated ahead. Lab error has resulted in the wrong blood being given to patients even in this situation. However, there is a difference in thinking of Optro as a blood replacement versus an oxygen theraputic. This was brought home well in the Stover report. With it's shorter halflife it is not as good a replacement. However, in surgery improvement in oxygenation for 6 to 12 hours may be enough to get one over the hump to where transfusion will not be required. I wouldn't be surprized to see some resistance in the medical community especially where there is a vested interest in blood banking. It's all about money you know. A very important benefit that has recently been raised is that Optro is not expected to have the same effect on the immune status of the patient. That will be important espcially in cancer patient where it has been shown that in patients recieving blood there are higher rates of recurrance felt to be immune related. In colon cancer if blood is given that group will have more recurrances. It will take time for such studies to be completed but once Optro is available I would expect it to be an area that will be pursued. Also Optro may be theraputic in situations when oxygenation of tissue is impaired by hardening of the arteries, ie. heart attack, stroke, peripheral vascular disease. If higher levels of oxygen can be delivered to areas with blockages less tissue damage will occur. Just food for thought.

Share	Recommend \| Keep \| Reply \| Mark as Last Read

Previous 10 | Next 10

Copyright/IP Policy

Copyright © 1995-2013 Knight Sac Media. All rights reserved.